MajdIssaMD

PubMed

• Effectiveness of Nasolacrimal SCC Treatments and Promising Role of Chemo-Induction: A Case Report and Systematic Review.
  Mohammad Bilal Alsavaf, Moataz D Abouammo, Govind S Bhuskute, Shuai Sun, Majd Issa, Nolan B Seim, Kyle K VanKoevering, Priyanka Bhateja, Marcelo Bonomi, Ricardo L Carrau> ;The Laryngoscope. 2024 Apr 23
• 3 citations
  Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer.
  Majd Issa, Joy Tang, Yizhen Guo, Chris Coss, Thomas A Mace, Jason Bischof, Mitch Phelps, Carolyn J Presley, Dwight H Owen> ;Expert Review of Anticancer Therapy. 2022 Aug 1
• Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort.
  Majd Issa, Brett G Klamer, Nikol Mladkova, Georgios I Laliotis, Vidhya Karivedu, Priyanka Bhateja, Chase Byington, Khaled Dibs, Xueliang Pan, Arnab Chakravarti, John G...> ;BMC Cancer. 2022 Jul 14
• Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer.
  Leeann Geraghty, Thomas E Schultz, Sarah Hoffman, Kyle Porter, Majd Issa, Vidhya Karivedu, Marcelo Bonomi> ;Molecular and Clinical Oncology. 2021 Sep 22
• 2 citations
  Treatment Outcomes of Head and Neck Cancer Patients in the Elderly Receiving Different Chemoradiation Combinations: A Single-Center Experience.
  Vidhya Karivedu, Marcelo Bonomi, Majd Issa, Adriana Blakaj, Brett Klamer, Xueliang Pan, Matthew O. Old, Priyanka Bhateja, Stephen Y. Kang, Nolan B. Seim, Enver Ozer, A...> ;Oncology Research and Treatment. 2021 Jan 1
• 3 citations
  Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report.
  Kai Johnson, Majd Issa, Anish B. Parikh, Paul Monk, Ming Yin, Amir Mortazavi, Yuanquan Yang> ;BMC Urology. 2021 Apr 1
• 5 citations
  A predictive survival model for patients with head and neck squamous cell carcinoma treated with immune check point inhibitors.
  Marcelo Bonomi, P. Bhateja, Majd Issa, Brett Klamer, Xueliang Jeff Pan, Adriana Blakaj, Vidhya Karivedu, L. Mousa, D.L. Mitchell, Mauricio E. Gamez, Stephen Y. Kang, N...> ;Oral Oncology. 2020 Jul 20
• 14 citations
  Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter st...
  Nieves Martinez Chanza, Wanling Xie, Majd Issa, Hannah Dzimitrowicz, Abhishek Tripathi, Benoit Beuselinck, Elaine T. Lam, Yousef Zakharia, Rana R. McKay, Sumit A. Shah...> ;Journal for Immunotherapy of Cancer. 2020 Mar 1
• 2 citations
  Clinical Course of Hypertrophic Pulmonary Osteoarthropathy in a Patient Receiving Immune Checkpoint Inhibitor Therapy.
  Andrew Johns, Chad Sorenson, Alan Rogers, Julia L. Agne, Desmond M. D’Souza, Jishu K. Das, Majd Issa, Gina Perna, Terence M. Williams, Alexa Meara, Trevor Kitchin, K.E...> ;Clinical Lung Cancer. 2020 Jan 27
• 4 citations
  Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck
  Misako Nagasaka, Mark Zaki, Majd Issa, Harold Kim, Judith Abrams, Ammar Sukari> ;The Laryngoscope. 2017 Oct 1
• Join now to see all